Genomics is bringing in a new wave of money from an unlikely group of investors — health systems. More providers are ...

Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.

Stellaromics, a start-up that uses multiomics technology to help researchers understand the spatial organization of cells and tissues, has raised $80 million in a series B financing. Catalyst4, a ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the ...

A Wednesday night earnings report left big questions about how the spending reductions would affect the company.

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

JPMorgan analyst Rachel Vatnsdal lowered the firm’s price target on 10x Genomics (TXG) to $12 from $14 and keeps a Neutral rating on the shares ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

Leerink downgraded 10x Genomics (TXG) to Market Perform from Outperform with a price target of $12, down from $25. Despite having the market ...

Researchers have successfully uncovered the molecular mechanisms by which bacterial cellulose patches stimulate the regeneration of plant wounds.   - The regeneration process requires the activation ...

CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...